These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36633908)

  • 1. Oral anticoagulants: A plausible new treatment for Alzheimer's disease?
    Toribio-Fernandez R; Ceron C; Tristão-Pereira C; Fernandez-Nueda I; Perez-Castillo A; Fernandez-Ferro J; Moro MA; Ibañez B; Fuster V; Cortes-Canteli M
    Br J Pharmacol; 2024 Mar; 181(6):760-776. PubMed ID: 36633908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline.
    Semerano A; Fernández-Ruiz J; Cortes-Canteli M; Moro MA
    Br J Pharmacol; 2024 Mar; 181(6):755-759. PubMed ID: 38204183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid cells in vascular dementia and Alzheimer's disease: Possible therapeutic targets?
    García-Culebras A; Cuartero MI; Peña-Martínez C; Moraga A; Vázquez-Reyes S; de Castro-Millán FJ; Cortes-Canteli M; Lizasoain I; Moro MÁ
    Br J Pharmacol; 2024 Mar; 181(6):777-798. PubMed ID: 37282844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of gut microbiota in cerebrovascular disease and related dementia.
    Cuartero MI; García-Culebras A; Nieto-Vaquero C; Fraga E; Torres-López C; Pradillo J; Lizasoain I; Moro MÁ
    Br J Pharmacol; 2024 Mar; 181(6):816-839. PubMed ID: 37328270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease.
    Bettinetti-Luque M; Trujillo-Estrada L; Garcia-Fuentes E; Andreo-Lopez J; Sanchez-Varo R; Garrido-Sánchez L; Gómez-Mediavilla Á; López MG; Garcia-Caballero M; Gutierrez A; Baglietto-Vargas D
    Br J Pharmacol; 2024 Mar; 181(6):840-878. PubMed ID: 37706346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms linking cerebrovascular dysfunction and tauopathy: Adding a layer of epiregulatory complexity.
    Kim YA; Mellen M; Kizil C; Santa-Maria I
    Br J Pharmacol; 2024 Mar; 181(6):879-895. PubMed ID: 37926507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astrocyte-derived lactoferrin reduces β-amyloid burden by promoting the interaction between p38 kinase and PP2A phosphatase in male APP/PS1 transgenic mice.
    Fan YG; Guo C; Zhao LX; Ge RL; Pang ZQ; He DL; Ren H; Wu TY; Zhang YH; Wang ZY
    Br J Pharmacol; 2024 Mar; 181(6):896-913. PubMed ID: 37309219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.
    Ittner LM; Klugmann M; Ke YD
    Br J Pharmacol; 2019 Sep; 176(18):3649-3665. PubMed ID: 30817847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short perspective on the long road to effective treatments for Alzheimer's disease.
    Reynolds DS
    Br J Pharmacol; 2019 Sep; 176(18):3636-3648. PubMed ID: 30657599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-angle development of therapeutic methods for Alzheimer's disease.
    Hoshi M
    Br J Pharmacol; 2021 Feb; 178(4):770-783. PubMed ID: 32592177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.
    Perez Ortiz JM; Swerdlow RH
    Br J Pharmacol; 2019 Sep; 176(18):3489-3507. PubMed ID: 30675901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine.
    Duce JA; Zhu X; Jacobson LH; Beart PM
    Br J Pharmacol; 2019 Sep; 176(18):3409-3412. PubMed ID: 31468515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulants for Treatment of Alzheimer's Disease.
    Grossmann K
    J Alzheimers Dis; 2020; 77(4):1373-1382. PubMed ID: 32925057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Alzheimer's disease by targeting iron.
    Nikseresht S; Bush AI; Ayton S
    Br J Pharmacol; 2019 Sep; 176(18):3622-3635. PubMed ID: 30632143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Don't forget astrocytes when targeting Alzheimer's disease.
    Sadick JS; Liddelow SA
    Br J Pharmacol; 2019 Sep; 176(18):3585-3598. PubMed ID: 30636042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The involvement of microglia in Alzheimer's disease: a new dog in the fight.
    Moore Z; Taylor JM; Crack PJ
    Br J Pharmacol; 2019 Sep; 176(18):3533-3543. PubMed ID: 30445661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex as a biological variable in the pathology and pharmacology of neurodegenerative and neurovascular diseases.
    Honarpisheh P; McCullough LD
    Br J Pharmacol; 2019 Nov; 176(21):4173-4192. PubMed ID: 30950038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the role of T cells in cognitive impairment.
    Ruiz-Fernández I; Sánchez-Díaz R; Ortega-Sollero E; Martín P
    Br J Pharmacol; 2024 Mar; 181(6):799-815. PubMed ID: 37559406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation and Alzheimer's disease: A conundrum.
    Benenati S; Canale C; De Marzo V; Della Bona R; Rosa GM; Porto I
    Eur J Clin Invest; 2021 Jul; 51(7):e13451. PubMed ID: 33219514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets.
    Nizami S; Hall-Roberts H; Warrier S; Cowley SA; Di Daniel E
    Br J Pharmacol; 2019 Sep; 176(18):3515-3532. PubMed ID: 30740661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.